Synonyms: AS-602801 | AS602801 | PGL-5001 | PGL5001
Compound class:
Synthetic organic
Comment: Bentamapimod (a.k.a. PGL-5001 and AS602801) is novel and orally active Jun kinase inhibitor (JNK1= MAPK8 and JNK2= MAPK9). It has shown preclinical efficacy that may be applied to the treatment of endometriotic lesions [1,3]. It also inhibits cancer stem cells in vitro and in vivo [2]. It was originally developed by Merck Seroneo (JNK-I AS602801) and then in-licensed by PregLem and re-named PGL5001 (PGL5 may also be used).
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
International Nonproprietary Names ![]() |
|
INN number | INN |
8919 | bentamapimod |
Synonyms ![]() |
AS-602801 | AS602801 | PGL-5001 | PGL5001 |
Database Links ![]() |
|
CAS Registry No. | 848344-36-5 (source: WHO INN record) |
ChEMBL Ligand | CHEMBL3545213 |
GtoPdb PubChem SID | 363894220 |
PubChem CID | 10195250 |
Search Google for chemical match using the InChIKey | XCPPIJCBCWUBNT-UHFFFAOYSA-N |
Search Google for chemicals with the same backbone | XCPPIJCBCWUBNT |
Search PubMed clinical trials | bentamapimod |
Search PubMed titles | bentamapimod |
Search PubMed titles/abstracts | bentamapimod |
UniChem Compound Search for chemical match using the InChIKey | XCPPIJCBCWUBNT-UHFFFAOYSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | XCPPIJCBCWUBNT-UHFFFAOYSA-N |
Product supplier links are provided as a service to assist in identifying commercial suppliers of reagents that are mentioned on the IUPHAR/BPS Guide to PHARMACOLOGY database website, and do not imply their endorsement by NC-IUPHAR.
Links are provided in return for sponsorship, used to fund improvements to this database. The sponsorship account is managed and audited by the University of Edinburgh, a charitable body registered in Scotland, SC005336. If you are interested in sponsoring the database, please contact us.
✖
Bentamapimod (links to external site)
Cat. No. HY-14761 |